Abstract
Eight patients with Philadelphia chromosome-positive (Ph+) leukaemia relapsing from stem cell transplantation (SCT) (one syngeneic and seven allogeneic) were treated with the tyrosine kinase inhibitor STI571. Five patients relapsing as chronic myeloid leukaemia (CML) in chronic phase achieved a complete haematological response, with complete and major cytogenetic responses occurring in four and one cases, respectively. One patient became negative for BCR/ABL in the bone marrow. Three patients relapsed as acute leukaemia (two CML in myeloblastic crisis and one Ph+ acute lymphoblastic leukaemia), all of whom achieved haematological and cytogenetic responses. One patient also became BCR/ABL negative. However, pancytopenia and graft-versus-host disease led to cessation of treatment in the remaining two cases, which was followed by disease recurrence refractory to further STI treatment. Our results showed that Ph+ leukaemic relapses after SCT might respond well to STI571 therapy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Druker BJ, Talpaz M, Resta DJ et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia New Engl J Med 2001 344: 1031 1037
Druker BJ, Sawyers CL, Kantarjian H et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome New Engl J Med 2001 344: 1038 1042
Mughal TI, Goldman JM . Chronic myeloid leukaemia. STI 571 magnifies the therapeutic dilemma Eur J Cancer 2001 37: 561 568
Baron F, Frere P, Fillet G, Beguin Y . Treatment of leukemia relapse after allogeneic hematopoietic stem cell transplantation by donor lymphocyte infusion and STI-571 Haematologica 2001 86: 993 994
Wassmann B, Klein SA, Scheuring U et al. Hematologic and cytogenetic remission by STI571 (Glivec) in a patient relapsing with accelerated phase CML after second allogeneic stem cell transplantation Bone Marrow Transplant 2001 28: 721 724
Kwong YL, Chiu EK, Liang RH et al. Essential thrombocythemia with BCR/ABL rearrangement Cancer Genet Cytogenet 1996 89: 74 76
Au WY, Chan AC, Lie AK et al. Isolated extramedullary relapse after allogeneic bone marrow transplantation for chronic myeloid leukemia Bone Marrow Transplant 1998 22: 99 102
Au WY, Lie AK, Ma SK et al. Therapy-related myelodysplastic syndrome of recipient origin after allogeneic bone marrow transplantation for acute lymphoblastic leukaemia Br J Haematol 2001 112: 424 426
O'Dwyer ME, Druker BJ . Chronic myelogenous leukaemia – new therapeutic principles J Intern Med 2001 250: 3 9
Carella AM, Frassoni F, Negrin RS . Autografting in chronic myelogenous leukemia: new questions Leukemia 1995 9: 365 369
Collins RH Jr, Shpilberg O, Drobyski WR et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation J Clin Oncol 1997 15: 433 444
Blau IW, Basara N, Bischoff M et al. Second allogeneic hematopoietic stem cell transplantation as treatment for leukemia relapsing following a first transplant Bone Marrow Transplant 2000 25: 41 45
Olavarria E, Craddock C, Dazzi F et al. Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantation Blood 2002 99: 3861 3862
Dazzi F, Szydlo RM, Goldman JM . Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplant: where we now stand Exp Hematol 1999 27: 1477 1486
Dazzi F, Szydlo RM, Craddock C et al. Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia Blood 2000 95: 67 71
Acknowledgements
The authors would like to thank C Liu and C Man for clerical and technical assistance. This study is supported by Novartis, Basel, and the Kadoorie Charitable Foundation.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Au, W., Lie, A., Ma, S. et al. Tyrosine kinase inhibitor STI571 in the treatment of Philadelphia chromosome-positive leukaemia failing myeloablative stem cell transplantation. Bone Marrow Transplant 30, 453–457 (2002). https://doi.org/10.1038/sj.bmt.1703678
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1703678
Keywords
This article is cited by
-
Autoimmune thyroid dysfunction after hematopoietic stem cell transplantation
Bone Marrow Transplantation (2005)